Drug Discovery Digital 2020 - Connect - Learn - Discover
Sygnature Discovery and RenaSci strengthen drug abuse leadership with appointment of Dr Andy Mead
Sygnature Discovery and RenaSci strengthen drug abuse leadership with appointment of Dr Andy Mead 9th September 2020 – Nottingham, UK – Sygnature Discovery, a world-leading integrated discovery and pre-clinical solutions provider, has appointed Dr Andy Mead as Director and Head of Drug Abuse and Substance Use Disorders at its integrated in vivo pharmacology company, RenaSci.
With 25 years’ experience in the science of drug abuse and addiction across academia, biotech and pharma (including NIDA, Merck, Pfizer and AstraZeneca), Dr Mead brings strategic and scientific leadership to a well-established team of drug abuse specialists, and will drive the development and expansion of the company’s non-clinical drug abuse and substance use disorders capabilities.
For Sygnature and RenaSci customers, this senior appointment adds a rare depth of expertise around non-clinical assessment and regulatory strategy, with Dr Mead bringing extensive experience across a wide range of abuse liability assessments, and will ensure expert collaboration and consultancy in meeting the regulatory requirements for drug abuse assessment during the development of novel therapeutic agents.
Dr Mead’s specialist knowledge in safety pharmacology and discovery toxicology will also complement and add value to the expertise already on offer across a variety of therapeutic areas at Sygnature.
Dr Andy Mead said: "I have always been passionate about the science of drug abuse and addiction and there is so much need for it today – both ensuring patient safety through the assessment of abuse liability, as well as directly addressing patient need through discovering novel treatments for substance use disorders.
“This role gives me the exciting opportunity to collaborate across all sectors of the healthcare industry to pursue both of those aspects, building on RenaSci’s established reputation for scientific quality and collaboration, and aligned with Sygnature Discovery's vision to deliver the best science through innovation and tailored integrated drug discovery and pre-clinical expertise."
Dr Mead joins Sygnature from Sosei Heptares, where he was Director of Discovery and Translational Safety. His industry experience is backed by an internationally-recognised publication record for developing the science of drug abuse and substance use disorders, extensive regulatory experience in the area of abuse liability; as well as a strong track record for progressing molecules from concept through to clinical development across a range of therapeutic areas.
Dr Simon Hirst, Founder and CEO at Sygnature, said: “The worldwide opioid crisis has brought the field of drug abuse liability and treatment to the forefront of science. But with the variety of models involved, it is an extremely complex undertaking. To advance new molecules to market, it is critical that both the quality of the science and the drug development strategy behind it are at the highest level.
“With a history of providing pre-clinical solutions in this challenging area, I am thrilled at the prospect of Andy joining to head-up a team of scientists with a world-renowned reputation. Andy’s experience will not only strengthen the expertise of this team, but as a well-respected and dynamic scientist he will ensure we remain at the fore-front of this exciting area.”

Posted: 9-Sep-2020

Sygnature Discovery
United Kingdom
01159415401 Main
busdev@sygnaturediscovery.com Email
Pennyfoot Street

https://www.sygnaturediscovery.com/ website

Hosted By
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo, Labhoo Ltd 2003-2020